ADVERTISEMENT
Netherlands
Country
The $8bn buyout could bring another blockbuster cancer therapy to Genmab but analysts think the firm has yet to prove itself in commercializing its own pipeline.
Fabrice Chouraqui is full of praise for the ‘amazing platform for growth’ established by predecessor Sijmen de Vries, which has left the Dutch firm poised to reap the rewards of its self-financing model.
Samsung Bioepis will not be able to add an ulcerative colitis indication to its ustekinumab biosimilar in the Netherlands for now, after failing to have a key patent revoked.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
In a further setback for generics manufacturers, the District Court of The Hague has upheld the validity of a key Xtandi (enzalutamide) patent and its Dutch supplementary protection certificate, rejecting Sandoz and Accord’s challenge based on lack of inventive step.
The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
A public interest group has accused the pharma major of using excessive pricing to bolster sales of blockbuster Humira, consequently damaging the health of Dutch patients.
Leadership changes at Norgine, IPHA and Orifarm feature in this week's round-up of European consumer health people news.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.